ProfileGDS5678 / 1449621_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 77% 79% 76% 79% 74% 78% 73% 66% 82% 81% 82% 84% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2191777
GSM967853U87-EV human glioblastoma xenograft - Control 25.2422277
GSM967854U87-EV human glioblastoma xenograft - Control 35.478279
GSM967855U87-EV human glioblastoma xenograft - Control 45.1728776
GSM967856U87-EV human glioblastoma xenograft - Control 55.5570879
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7035874
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3109478
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7508373
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9507366
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.927182
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7308381
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0646982
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2538984
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8971482